Akebia Therapeutics (AKBA) FCF Margin (2017 - 2026)
Akebia Therapeutics (AKBA) posted quarterly FCF Margin of 41.01% for Q1 2026, down 1728.0% year-over-year from 2.52% in Q1 2025, and down 182.25% quarter-over-quarter from 49.86% in Q4 2025.
Akebia Therapeutics (AKBA) FCF Margin (2017 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported FCF Margin for 10 consecutive years, with 41.01% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 1728.0% year-over-year to 41.01%; the TTM figure through Mar 2026 stood at 24.53% (up 4270.0% YoY), while the FY2025 annual figure was 27.68%, up 5267.0% from the prior year.
- FCF Margin fell to 41.01% in Q1 2026 per AKBA's latest filing, from 49.86% in the prior quarter.
- Across five years, FCF Margin topped out at 49.86% in Q4 2025 and bottomed at 23228.95% in Q1 2022.
- Historically, FCF Margin has averaged 1376.73% across 5 years, with a median of 19.48% in 2022.
- Annual changes were most pronounced in 2022 — FCF Margin tumbled 2309629 bps — and 2023, when it jumped 2317808 bps.
- Akebia Therapeutics' FCF Margin stood at 98.02% in 2022, then jumped by 111 bps to 10.44% in 2023, then sank by 179 bps to 8.2% in 2024, then surged by 708 bps to 49.86% in 2025, then plunged by 182 bps to 41.01% in 2026.
- Business Quant data shows AKBA's FCF Margin at 41.01% in Q1 2026, 49.86% in Q4 2025, and 47.69% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.41% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 21.80% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 14.87% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 26.25% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 8.76% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 13.41% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 17.84% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 6.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.38% |
| Mar 31, 2026 | -41.01% |
| Dec 31, 2025 | 49.86% |
| Sep 30, 2025 | 47.69% |
| Jun 30, 2025 | 35.57% |
| Mar 31, 2025 | -23.73% |
| Dec 31, 2024 | -8.20% |
| Sep 30, 2024 | -19.18% |
| Jun 30, 2024 | -20.62% |
| Mar 31, 2024 | -61.47% |
| Dec 31, 2023 | 10.44% |
| Sep 30, 2023 | -36.49% |
| Jun 30, 2023 | 11.43% |
| Mar 31, 2023 | -50.87% |
| Dec 31, 2022 | -98.02% |
| Sep 30, 2022 | 48.61% |
| Jun 30, 2022 | -19.48% |
| Mar 31, 2022 | -23,228.95% |
| Dec 31, 2021 | 41.30% |
| Sep 30, 2021 | -124.04% |